Mumbai: Sun Pharmaceutical Industries reported a growth of 62 percent in its net sales for the quarter ending June 30, 2012, over same quarter last year. The income stood at approximately $480 million (Rs 2658 crore).

Branded generic sales in India, at approximately $106 million (Rs 588 crore), fell by eight percent over the same period last year. This is on account of significantly higher sales in Q4 FY12. US finished dosage sale is $285 million, and grew by 105 percent (in $ terms) over Q1 (April-June) last year. International formulation sales is $68 million, and grew by 20 percent (in $ terms) over same quarter last year.

Dilip Shanghvi, managing director of the company, said, "Over the years, we have focused on building a consistent, predictable and profitable business. The performance this quarter is once again a reflection of this strength. The year has begun well as we have reported strong underlying growth across all our business segments."